BioCryst Pharmaceuticals ...

NASDAQ: BCRX · Real-Time Price · USD
8.41
-0.04 (-0.47%)
At close: Aug 15, 2025, 1:13 PM

BioCryst Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
450.71M 331.41M 270.83M 157.17M
Cost of Revenue
12.27M 4.66M 6.59M 7.26M
Gross Profit
438.44M 325.1M 262.8M 149.13M
Operating Income
-2.54M -103.71M -148.44M -177.72M
Interest Income
14.75M 15.78M 5.13M 62K
Pretax Income
-86.95M -226.23M -244.38M -181.81M
Net Income
-88.88M -226.54M -247.12M -184.06M
Selling & General & Admin
266.13M 213.89M 159.37M 118.82M
Research & Development
174.64M 216.57M 253.3M 208.81M
Other Expenses
216K n/a n/a n/a
Operating Expenses
440.99M 430.46M 412.67M 118.82M
Interest Expense
98.52M 108.24M 99.09M 59.29M
Selling & Marketing Expenses
n/a 14.4M 14.89M 5.71M
Cost & Expenses
453.25M 435.12M 419.26M 334.89M
Income Tax Expense
1.93M 310K 2.73M 2.25M
Shares Outstanding (Basic)
206.7M 192.2M 185.91M 179.12M
Shares Outstanding (Diluted)
206.7M 192.2M 185.91M 179.12M
EPS (Basic)
-0.43 -1.18 -1.33 -1.03
EPS (Diluted)
-0.43 -1.18 -1.33 -1.03
EBITDA
12.81M -116.33M -143.85M -121.74M
EBIT
11.56M -117.99M -145.29M -122.52M
Depreciation & Amortization
1.25M 1.66M 1.44M 777K